MOLECULAR CARACTERISATION OF SOFT TISSUE SARCOMAS WITH COMPLEX GENETICS
description
Transcript of MOLECULAR CARACTERISATION OF SOFT TISSUE SARCOMAS WITH COMPLEX GENETICS
MOLECULAR CARACTERISATION OFSOFT TISSUE SARCOMAS WITH
COMPLEX GENETICS
Frédéric ChibonPauline Lagarde - Jean-Michel Coindre - Alain Aurias
Tumor GeneticsDépartement of Pathology
Insititut Bergonie – Bordeaux - FRANCE
GENETIC CLASSIFICATION OF STS
Sarcomas with recurrent translocations
Sarcomas with oncogenic mutations
Sarcomas with simple genetics
Sarcomas with a complex genetic profile
SARCOMAS WITH A COMPLEX GENETIC PROFILE
Leiomyosarcomas
Adult Rhabdomyosarcomas
Pleomorphic Liposarcomas
Myxofibrosarcomas
Poorly-differentiated sarcomas / MFH
SARCOMAS WITH A COMPLEX GENETIC PROFILE
Different prognosis but….… Difficult to classify !
share similar morphology
Share histological patterns with dedifferentiated liposarcomas
Genetic mechanisms still poorly understood
French Sarcoma Group Database
2538 adult STS with untreated primary tumor:(January 2006)
Well differentiated and dedifferentiated LPS: 262 (10.3%)
LMS, adult RMS, pleomorphic LPS, MFS and Poorly-Differentiated Sarcomas (PDS) / MFH:
1183 (46.6%)
Analyzed tumors: CGH ARRAY: 203cDNA ARRAY: 170
LPS DD30%
LMS 35%
MFH-PDS 35%
COMPLEX GENETIC PROFIL OF SOFT TISSUE SARCOMAS
MFH 50%MFS 25%PDS 25%
DD LPS
LMS
MFH+
PDS
Two main subgroups of genetic profiles
Amplification Gain Loss
DD LPS: Simple Genetics based on co-amplifications
Amplification Gain Loss
MDM2 is amplified without CDK4 in 10% of the tumorsSimple and specific genetics: 10 /40 were misdiagnosed
DD LPS
LMS
MFH
Two different profils correspond to two different types of LMS
LIMB
TRUNK
Ext
Int
10q23 13q14
10q 13q141q23-qter 17p12
17p13
5p16q12-q227p
Amplification Gain Loss
Average rearrangement number: 37
Average rearrangement number: 26
LIMB
TRUNK
Identification of a target gene
Non Amplified tumors
Amplified tumors
23 Mb
CGH ARRAY cDNA ARRAY
Identification of driver genes in amplifications
Chr 5
PDS / MFH LMS DD LPS
T e m p s e n m o i s1 6 8 , 0 0 01 4 4 , 0 0 01 2 0 , 0 0 09 6 , 0 0 07 2 , 0 0 04 8 , 0 0 02 4 , 0 0 00 , 0 0 0
Pro
bab
ilité
1 , 0
0 , 8
0 , 6
0 , 4
0 , 2
0 , 0
g a in o u a m p l i - c e n s u r ép e r t e o u n o r m - c e n s u r ég a in o u a m p l ip e r t e o u n o r m
c 2 _ t r i o
s u r v i e
5p
p=0,08
Overall Survival
Time in monthspr
obab
ility
Normal or loss
Amplification or gain
T e m p s e n m o i s8 4 , 0 0 07 2 , 0 0 06 0 , 0 0 04 8 , 0 0 03 6 , 0 0 02 4 , 0 0 01 2 , 0 0 00 , 0 0 0
Pro
bab
ilité
1 , 0
0 , 8
0 , 6
0 , 4
0 , 2
0 , 0
g a in o u a m p l i - c e n s u r ép e r t e o u n o r m - c e n s u r ég a in o u a m p l ip e r t e o u n o r m
c 2 _ t r i o
G r o u p e M F H S u r v i e e n f c t d e T r i o
5p
p=0,04
Overall SurvivalMFH
Time in months
prob
abili
ty
Normal or loss
Amplification or gain
5p Amplification : One gene amplified, up-regulated.......Wich effect on the tumor biology ?
Genetic alterations and clinical datas
T e m p s e n m o i s1 6 8 , 0 0 01 4 4 , 0 0 01 2 0 , 0 0 09 6 , 0 0 07 2 , 0 0 04 8 , 0 0 02 4 , 0 0 00 , 0 0 0
Pro
bab
ilité
1 , 0
0 , 8
0 , 6
0 , 4
0 , 2
0 , 0
g a in o u a m p l i - c e n s u r ép e r t e o u n o r m - c e n s u r ég a in o u a m p l ip e r t e o u n o r m
c 2 _ t r i o
M é t a
5p
p=0,08
Metastasis
Time in months
prob
abili
ty
Normal or loss
Amplification or gain
CONCLUSION
Scientific project based on a virtual tumor bank with all clinical, pathological, biological criterias and follow up
Identification of genomic alterations and target genes1q21-q245p7p10q13q17p
CGH: a really helpfull tool in STS diagnosis
At least TWO distinct LMS
Complementarity of CGH and cDNA arrays
DiagnosisPrognosisTherapeutic target
MFH / PDS with « LMS alterations » have to be reviewed by pathologist
MOLECULAR CARACTERISATION OF STS WITH COMPLEX GENETICS
Alain AuriasCaroline Louis
Jean-Michel CoindreBinh Nguyen BuiPauline LagardeVéronique BrousteCécile Garcia
11 CLCCFrench Sarcoma Group Pathologist